Clinical trials of resveratrol
Clinical trials of resveratrol
复制标题
DOI：
10.1111/j.1749-6632.2010.05853.x
复制
发表时间：
2011-01-01
期刊：
影响因子：
--
通讯作者：
Brown, Karen
中科院分区：
文献类型：
--
作者：
Patel, Ketan R.;Scott, Edwina;Brown, Karen
越来越多的临床前证据表明，白藜芦醇有可能影响多种人类疾病。为了将令人鼓舞的实验结果转化为对人类的好处，首先需要关于白藜芦醇的安全性、药动学、药效学以及最终的临床疗效的信息。已发表的临床试验主要集中在白藜芦醇的药代动力学和代谢特征上。最近的研究还评估了多次给药后的安全性和潜在的活性机制，并发现白藜芦醇在每天剂量高达5g时是安全的，耐受性相当好。然而，轻微到中度副作用的发生可能会将未来试验中使用的剂量限制在明显低于这一数量的水平。这篇综述描述了现有的临床数据，概述了它如何支持白藜芦醇的持续开发，并建议需要哪些额外的信息来增加未来临床试验的成功机会。
An expanding body of preclinical evidence suggests resveratrol has the potential to impact a variety of human diseases. To translate encouraging experimental findings into human benefits, information is first needed on the safety, pharmacokinetics, pharmacodynamics, and, ultimately, clinical efficacy of resveratrol. Published clinical trials have largely focused on characterizing the pharmacokinetics and metabolism of resveratrol. Recent studies have also evaluated safety and potential mechanisms of activity following multiple dosing, and have found resveratrol to be safe and reasonably well-tolerated at doses of up to 5 g/day. However, the occurrence of mild to moderate side effects is likely to limit the doses employed in future trials to significantly less than this amount. This review describes the available clinical data, outlines how it supports the continuing development of resveratrol, and suggests what additional information is needed to increase the chances of success in future clinical trials.